Citations

Showing 10 of 108104 citations.

The Best Plastic Surgeons Are the Best Anatomists: Evaluation of a Training Method and Residents as Teachers
Noland, Shelley S. , Nuland, Sonya Van, Casey, William J., Smith, Anthony A., Pflibsen, Lacey R. , Langley, Natalie R.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | July 19, 2018 | Volume: 6 | Issue: 7 | Pages: e1815

10.1097/gox.0000000000001815 Get It

CORR Insights®: Do Early Results of Proximal Humeral Allograft-Prosthetic Composite Reconstructions Persist at 5-year Followup?
Houdek, Matthew T.

Mayo Clinic

Clinical Orthopaedics & Related Research | July 19, 2018 | Volume: 477 | Issue: 4 | Pages: 766-767

10.1097/corr.0000000000000417 | PMID 30024465 Get It

Sex differences in large conducting airway anatomy
Dominelli, Paolo B. , Ripoll, Juan G. , Cross, Troy J. , Baker, Sarah E. , Wiggins, Chad C. , Welch, Brian T. , Cross, Troy James , Wiggins, Chad C , Baker, Sarah E , Joyner, Michael J.

Mayo Clinic

Journal of Applied Physiology | July 19, 2018 | Volume: 125 | Issue: 3 | Pages: 960-965

10.1152/japplphysiol.00440.2018 | PMID 30024341 Get It

Airway luminal area is the major determinant of resistance to airflow in the tracheobronchial tree. Women may have smaller central conducting airways than men; however, previous evidence is confounded by an indirect assessment of airway geometry and by subjects with prior smoking history. The purpose of this study was to examine the effect of sex on airway size in healthy nonsmokers. Using low-dose high-resolution computed tomography, we retrospectively assessed airway luminal area in healthy men ( n = 51) and women ( n = 73) of varying ages (19–86 yr). Subjects with a positive smoking history, cardiopulmonary disease, or a body mass index > 40 kg/m2 were excluded. Luminal areas of the trachea, right and left main bronchus, bronchus intermediate, left and right upper lobes, and the left lower lobe were analyzed at three discrete points. The luminal areas of the conducting airways were ~26%–35% smaller in women. The trachea had the largest differences in luminal area between men and women (298 ± 47 vs. 195 ± 28 mm2 or 35% smaller for men and women, respectively), whereas the left lower lobe had the smallest differences (57 ± 15 vs. 42 ± 9 mm2 or 26% smaller for men and women, respectively). When a subset of subjects was matched for height, the sex differences in airway luminal area persisted, with women being ~20%–30% smaller. With all subjects, there were modest relationships between height and airway luminal area ( r = 0.73–0.53, P < 0.05). Although there was considerable overlap between sexes, the luminal areas of the large conducting airways were smaller in healthy women than in men. NEW & NOTEWORTHY Previous evidence for sex differences in airway size has been confounded by indirect measures and/or cohorts with significant smoking histories or pathologies. We found that central airways in healthy women were significantly smaller (~26%–35%) than men. The significant sex-difference in airway size was attenuated (20%–30% smaller) but preserved in a subset of subjects matched for height. Over a range of ages, healthy women have smaller central airways than men.
Association between obesity and pediatric psoriasis
Hunjan, Manrup , Kremers, Hilal Maradit , Lohse, Christine M. , Tollefson, Megha M. , Hunjan, Manrup K , Maradit Kremers, Hilal, Lohse, Christine, Tollefson, Megha, Maradit Kremers, Hilal

Mayo Clinic

Pediatric Dermatology | July 19, 2018 | Volume: 35 | Issue: 5 | Pages: No page available

10.1111/pde.13539 | PMID 30024063 Get It

AbstractObese children are at higher risk of developing psoriasis, and obesity severity is correlated with psoriasis severity. The relationship between obesity and pediatric psoriasis was explored in a well‐defined population. Obesity and psoriasis coexist at diagnosis, but it is likely that obesity commonly precedes psoriasis in children.
Randomized Trial of Spheroid Reservoir Bioartificial Liver in Porcine Model of Posthepatectomy Liver Failure
Chen, Harvey S., Joo, Dong Jin , Shaheen, Mohammed F. , Li, Yi , Wang, Yujia , Nicolas, Clara T., Predmore, Kelly, Amiot, Bruce , Michalak, Gregory, Mounajjed, Taofic, Fidler, Jeff L. , Kremers, Walter K. , Nyberg, Scott L. , Shaheen, Mohammed, Fidler, Jeff, Kremers, Walter K , Yang, Jian , Predmore, Kelly S, Fidler, Jeff L.

Mayo Clinic

Hepatology | July 19, 2018 | Volume: 69 | Issue: 1 | Pages: 329-342

10.1002/hep.30184 | PMID 30022502 Get It

Acute liver failure (ALF) is a catastrophic condition that can occur after major liver resection. The aim of this study was to determine the effects of the spheroid reservoir bio‐artificial liver (SRBAL) on survival, serum chemistry, and liver regeneration in posthepatectomy ALF pigs. Wild‐type large white swine (20 kg‐30 kg) underwent intracranial pressure (ICP) probe placement followed by 85% hepatectomy. Computed tomography (CT) volumetrics were performed to measure the extent of resection, and at 48 hours following hepatectomy to assess regeneration of the remnant liver. Animals were randomized into three groups based on treatment delivered 24‐48 hours after hepatectomy: Group1—standard medical therapy (SMT, n = 6); Group2—SMT plus bio‐artificial liver treatment using no hepatocytes (0 g, n = 6); and Group3—SMT plus SRBAL treatment using 200 g of primary porcine hepatocyte spheroids (200 g, n = 6). The primary endpoint was survival to 90 hours following hepatectomy. Death equivalent was defined as unresponsive grade 4 hepatic encephalopathy or ICP greater than 20 mmHg with clinical evidence of brain herniation. All animals in both (SMT and 0 g) control groups met the death equivalent before 51 hours following hepatectomy. Five of 6 animals in the 200‐g group survived to 90 hours ( P < 0.01). The mean ammonia, ICP, and international normalized ratio values were significantly lower in the 200‐g group. CT volumetrics demonstrated increased volume regeneration at 48 hours following hepatectomy in the 200‐g group compared with the SMT ( P < 0.01) and 0‐g (P < 0.01) groups. Ki‐67 staining showed increased positive staining at 48 hours following hepatectomy ( P < 0.01). Conclusion: The SRBAL improved survival, reduced ammonia, and accelerated liver regeneration in posthepatectomy ALF. Improved survival was associated with a neuroprotective benefit of SRBAL therapy. These favorable results warrant further clinical testing of the SRBAL.
Lung transplant patients with coronary artery disease rarely die of cardiac causes
Makey, Ian A. , Sui, Jin W., Huynh, Charles, Das, Nitin A. , Thomas, Mathew , Johnson, Scott, Thomas, Mathew , Thomas, Mathew , Huynh, Charles, Thomas, Mathew

Mayo Clinic

Clinical Transplantation | July 19, 2018 | Volume: 32 | Issue: 9 | Pages: No page available

10.1111/ctr.13354 | PMID 30022532 Get It

AbstractBackgroundA relative contraindication for lung transplant (LT) is coronary disease burden sufficient to cause risk of myocardial infarction after LT. We analyzed cause of death and outcomes of our LT patients with coronary artery disease (CAD).MethodsInpatient records from March 1, 2004, to January 31, 2015, were retrospectively examined and data of 306 LTs extracted. Twenty‐five patients without coronary angiography (CA) and 7 with redo LTs were excluded. The other 274 patients were divided into 2 groups: CAD (n = 116) and no CAD (n = 158). Patients with prior revascularization or coronary stenosis >10% were placed into the CAD group.ResultsThe CAD group was older and had more male patients, greater history of smoking and hypertension, and greater proportion of patients with interstitial lung disease than the no‐CAD group. CAD patients were more likely to receive a single‐lung transplant. Death of cardiac causes occurred for 2 patients (1.7%) in the CAD group and for 1 patient (0.6%) in the no‐CAD group (P = 0.39).ConclusionsThis analysis shows that compared with patients who have no CAD, patients with CAD have different demographic characteristics and receive more single‐lung transplants. Incidence of death of cardiac causes is rare.
End of Life, Withdrawal, and Palliative Care Utilization among Patients Receiving Maintenance Hemodialysis Therapy
Chen, Joy Chieh-Yu, Vaughan, Lisa E. , Feely, Molly A., Albright, Robert C. , Norby, Suzanne M. , Gossett, Christy, d’Uscio, Margaret, Williams, Amy W. , Hickson, LaTonya J. , Onuigbo, Macaulay , Norby, Suzanne M , Hickson, LaTonya J , Chen, Joy Chieh-Yu, Thorsteinsdottir, Bjorg , Dillon, John

Mayo Clinic

Clinical Journal of the American Society of Nephrology | July 19, 2018 | Volume: 13 | Issue: 8 | Pages: 1172-1179

10.2215/cjn.00590118 | PMID 30026285 Get It

Background and objectives Withdrawal from maintenance hemodialysis before death has become more common because of high disease and treatment burden. The study objective was to identify patient factors and examine the terminal course associated with hemodialysis withdrawal, and assess patterns of palliative care involvement before death among patients on maintenance hemodialysis. Design, setting, participants, & measurements We designed an observational cohort study of adult patients on incident hemodialysis in a midwestern United States tertiary center, from January 2001 to November 2013, with death events through to November 2015. Logistic regression models evaluated associations between patient characteristics and withdrawal status and palliative care service utilization. Results Among 1226 patients, 536 died and 262 (49% of 536) withdrew. A random sample (10%; 52 out of 536) review of Death Notification Forms revealed 73% sensitivity for withdrawal. Risk factors for withdrawal before death included older age, white race, palliative care consultation within 6 months, hospitalization within 30 days, cerebrovascular disease, and no coronary artery disease. Most withdrawal decisions were made by patients (60%) or a family member (33%; surrogates). The majority withdrew either because of acute medical complications (51%) or failure to thrive/frailty (22%). After withdrawal, median time to death was 7 days (interquartile range, 4–11). In-hospital deaths were less common in the withdrawal group (34% versus 46% nonwithdrawal, P =0.003). A third (34%; 90 out of 262) of those that withdrew received palliative care services. Palliative care consultation in the withdrawal group was associated with longer hemodialysis duration (odds ratio, 1.19 per year; 95% confidence interval, 1.10 to 1.3; P <0.001), hospitalization within 30 days of death (odds ratio, 5.78; 95% confidence interval, 2.62 to 12.73; P <0.001), and death in hospital (odds ratio, 1.92; 95% confidence interval, 1.13 to 3.27; P =0.02). Conclusions In this single-center study, the rate of hemodialysis withdrawals were twice the frequency previously described. Acute medical complications and frailty appeared to be driving factors. However, palliative care services were used in only a minority of patients.
Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
Edwards, Marie E., Irazabal, María V. , Ofstie, Troy G., Bungum, Lisa A., Metzger, Andrew J., Senum, Sarah R. , Hogan, Marie C. , Kline, Timothy L. , Harris, Peter C. , Czerwiec, Frank S., Torres, Vicente E. , El-Zoghby, Ziad M, Kline, Timothy L , Harris, Peter C , Torres, Vicente E , Senum, Sarah R , Irazabal, Maria V , Chebib, Fouad T. , Zoghby, Ziad , Hogan, Marie C

Mayo Clinic

Clinical Journal of the American Society of Nephrology | July 19, 2018 | Volume: 13 | Issue: 8 | Pages: 1153-1161

10.2215/cjn.01520218 | PMID 30026287 Get It

Background and objectives In the 3-year Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes (TEMPO) 3:4 and 1-year Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trials, tolvaptan slowed the decline of eGFR in patients with autosomal dominant polycystic kidney disease at early and later stages of CKD, respectively. Our objective was to ascertain whether the reduction associated with the administration of tolvaptan is sustained, cumulative, and likely to delay the need for kidney replacement therapy. Design, setting, participants, & measurements One hundred and twenty-eight patients with autosomal dominant polycystic kidney disease participated in clinical trials of tolvaptan at the Mayo Clinic. All had the opportunity to enroll into open-label extension studies. Twenty participated in short-term studies or received placebo only. The remaining 108 were analyzed for safety. Ninety seven patients treated with tolvaptan for ≥1 year (mean±SD, 4.6±2.8; range, 1.1–11.2) were analyzed for efficacy using three approaches: ( 1 ) comparison of eGFR slopes and outcome (33% reduction from baseline eGFR) to controls matched by sex, age, and baseline eGFR; ( 2 ) Stability of eGFR slopes with duration of follow-up; and ( 3 ) comparison of observed and predicted eGFRs at last follow-up. Results Patients treated with tolvaptan had lower eGFR slopes from baseline (mean±SD, −2.20±2.18 ml/min per 1.73 m 2 per year) and from month 1 (mean±SD, −1.97±2.44 ml/min per 1.73 m 2 per year) compared with controls (mean±SD, −3.50±2.09 ml/min per 1.73 m 2 per year; P <0.001), and lower risk of a 33% reduction in eGFR (risk ratio, 0.63; 95% confidence interval, 0.38 to 0.98 from baseline; risk ratio, 0.53; 95% confidence interval, 0.31 to 0.85 from month 1). Annualized eGFR slopes of patients treated with tolvaptan did not change during follow-up and differences between observed and predicted eGFRs at last follow-up increased with duration of treatment. Conclusions Follow-up for up to 11.2 years (average 4.6 years) showed a sustained reduction in the annual rate of eGFR decline in patients treated with tolvaptan compared with controls and an increasing separation of eGFR values over time between the two groups.
Laparoscopic Donor Hepatectomy for Adult Living Donor Liver Transplantation Recipients
Kwon, Choon Hyuck David , Kim, Gaab Soo , Choi, Gyu‐Seong , Kim, Jong Man , Cho, Chan Woo , Rhu, Jinsoo , Sinn, Dong Hyun , Joh, Jae-Won

Mayo Clinic

Liver Transplantation | July 19, 2018 | Volume: 24 | Issue: 11 | Pages: 1545-1553

10.1002/lt.25307 | PMID 30021060 Get It

Even after 2 decades of experience in laparoscopic hepatectomy, data on purely laparoscopic approach for donor hepatectomy in adult living donor liver transplantation (LDLT) are limited. We report our initial experience of a purely laparoscopic approach for donor hepatectomy for adult recipients to explore its potential application in the management of donors. We did a retrospective data analysis of 54 consecutive patients operated on between May 2013 and February 2015. There were 41 right, 10 extended right, and 3 left hepatectomies. The median operative time was 436 minutes (range 294‐684 minutes), and warm ischemia time was 6 minutes (2‐12 minutes). Estimated blood loss was 300 mL (10‐850 mL), and none of the patients required intraoperative transfusion. Four cases were converted to open laparotomy. The major complication rate was 16.7%, and biliary complication was the most frequent cause. Patients with normal anatomy had a major complication rate of 9.3% as compared with 45.5% in patients with anatomic variations. All patients recovered, and there was no mortality. In conclusion, a purely laparoscopic donor hepatectomy for adult LDLT recipients seems to be a feasible option; with careful patient selection and when performed by experienced surgeons, it may afford results comparable to the open method.
A Prognosis for Health Systems Science Courses: Observations From Current Students
Mastorakos, George , Richter, Kent R. , Asprey, Walker L., Pines, Andrew R. , Khurana, Aditya

Mayo Clinic

Academic Medicine | July 19, 2018 | Volume: 93 | Issue: 10 | Pages: 1434-1436

10.1097/acm.0000000000002369 | PMID 30024476 Get It

Certain medical schools have begun teaching courses in health systems science (HSS) to train medical students in skills aimed to improve health care in the United States. Although substantial research has been done on the potential benefit of HSS courses, reactions from students have not been reported. In this Invited Commentary, five medical students who have completed the first year of a longitudinal HSS course at the Arizona campus of the Mayo Clinic School of Medicine offer their observations of how early exposure to HSS affected their reactions to subsequent course work and current events in health care. The authors describe the HSS course and outline three benefits they have observed from their experience so far: (1) thinking more critically about health care delivery during all educational experiences, (2) gaining a better understanding of the complexity of the health care system, and (3) having a greater consideration for the many facets of health care delivery. The HSS course helped the authors identify health systems problems, develop solutions that incorporated diverse domains of health care delivery, and recognize the role and responsibility of the physician as an agent of change in a health care system.